Prof. David Sinclair
Co-director, Paul F. Glenn Center for Biology of Aging Research | Harvard Medical School
About
Australian biologist whose lab helped clarify sirtuin biology and the role of NAD+ in aging. He founded Sirtris Pharmaceuticals (acquired by GSK) and co-authored Lifespan (2019), a popular-science book that brought NMN and NAD+ precursor discussion to a mainstream audience.
Key contributions
- Advanced sirtuin and NAD+ biology in aging research
- Popularised NAD+ precursor discussion for mainstream longevity audiences
- Co-authored Lifespan (2019), a popular-science longevity book
Publications in our knowledge base (12)
Every paper below is cited at least once across NMN Malaysia articles. Click any title to read the source on PubMed/DOI and see the cluster of articles that depend on its findings.
- Long-term NMN treatment increases lifespan and healthspan in mice in a sex dependent manner
- Preclinical animal study in bioRxiv (2024) investigating NAD+/NMN pathway mechanisms
- Findings inform translational rationale; not yet replicated in humans
- Mechanistic data on tissue-specific NAD+ effects
- Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Older Adults: A Physiologic Study
- Human study published in J Clin Endocrinol Metab (2023) examining Nicotinamide Adenine Dinucleotide Augmentation in Overweight or Obese Middle-Aged and Olde...
- Provides clinical-grade evidence on NAD+/NMN-related outcomes in human participants
- First author: Pencina KM; cited frequently in NMN supplementation discussions
- SIRT3 overexpression in rat muscle does not ameliorate peripheral insulin resistance
- Preclinical animal study in J Endocrinol (2023) investigating NAD+/NMN pathway mechanisms
- Findings inform translational rationale; not yet replicated in humans
- Mechanistic data on tissue-specific NAD+ effects
- Host-microbiome interactions in nicotinamide mononucleotide (NMN) deamidation
- Mechanistic study in FEBS Lett (2023) on NAD+/sirtuin/longevity biology
- Adds to the foundational literature underlying NMN supplementation rationale
- First author: Kim LJ
- Liver-specific overexpression of SIRT3 enhances oxidative metabolism, but does not impact metabolic defects induced by high fat feeding in mice
- Preclinical animal study in Biochem Biophys Res Commun (2022) investigating NAD+/NMN pathway mechanisms
- Findings inform translational rationale; not yet replicated in humans
- Mechanistic data on tissue-specific NAD+ effects
- Administration of Nicotinamide Mononucleotide (NMN) Reduces Metabolic Impairment in Male Mouse Offspring from Obese Mothers
- Preclinical animal study in Cells (2020) investigating NAD+/NMN pathway mechanisms
- Findings inform translational rationale; not yet replicated in humans
- Mechanistic data on tissue-specific NAD+ effects
- Neuroprotective effects and mechanisms of action of nicotinamide mononucleotide (NMN) in a photoreceptor degenerative model of retinal detachment
- Preclinical animal study in Aging (Albany NY) (2020) investigating NAD+/NMN pathway mechanisms
- Findings inform translational rationale; not yet replicated in humans
- Mechanistic data on tissue-specific NAD+ effects
- NAD+ in brain aging and neurodegenerative disorders
- Brain NAD+ decline with age
- Neurodegenerative disease links
- Therapeutic NAD+ replenishment outlook
- Lifespan: Why We Age - and Why We Don't Have To
- Popular-science book that helped bring NAD+ and longevity research to a mainstream consumer audience
- Useful as a source for public communication history, not as clinical evidence for NMN efficacy
- Clinical claims on NMN should be weighted against peer-reviewed human trials rather than book framing alone
- Telomere Dysfunction Induces Sirtuin Repression that Drives Telomere-Dependent Disease
- Mechanistic study in Cell Metab (2019) on NAD+/sirtuin/longevity biology
- Adds to the foundational literature underlying NMN supplementation rationale
- First author: Amano H
- Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
- Critical review of NAD+ booster evidence quality
- Identifies gaps between mouse and human data
- Sinclair-authored - author NMN evangelist context
- NAD+ and sirtuins in aging and disease
- Foundational review on sirtuin/NAD+ biology underlying NMN rationale
- NAD+ decline with age framework
- Imai's lab original framework
Why their work matters for Malaysian buyers
Prof. David Sinclair's research forms part of the evidence base we use to evaluate NMN and NR products available in Malaysia. When we make claims about dose ranges, safety, mechanism, or efficacy on this site, those claims trace back through papers like the ones above. The Malaysian regulatory framework (NPRA notification, JAKIM halal certification) does not perform efficacy review on supplements - buyers must do their own evidence weighting. Researcher profiles help you verify that the underlying science is robust, not just marketing.
How we cite this work
Every NMN Malaysia article that depends on findings from Prof. David Sinclair's lab carries an inline citation linking to a structured PubMed entry. You can verify any claim by clicking the citation and reading the source. This cited-research model is the bedrock of our editorial policy - see the 4-step review process for how we handle every health claim.
Related researchers
Browse other profiles: David Sinclair | Shinichiro Imai | Jun Yoshino | Charles Brenner | all profiles.